Mason Capital Management LLC, a Delaware limited liability company, has announced an extension to its existing tender offer for the American depositary shares and ordinary shares of Forward Pharma A/S. The new expiration date for this offer is set for July 10, 2024. Initially set to expire on June 26, 2024, the offer involves a purchase price of $437.00 per ADS and 0.76 DKK per Ordinary Share, based on the Tender Offer Materials dated May 14, 2024. As of June 26, 2024, a total of 1306 ADSs had been tendered, while no ordinary shares were tendered. Mason Capital continues to negotiate with the Bank of New York Mellon regarding the treatment of ordinary shares surrendered against the ADSs by the Settlement Date. Mason Capital emphasizes that the tender offer is subject to the conditions described in the Tender Offer Materials and advises shareholders to make their own decisions regarding participation. Mason Capital has assets under management worth $1.37 billion as of December 31, 2023, and has an absolute return focus.

Private Equity / Hedge Funds, Pharmaceuticals / Biotech,United States, Denmark